Inbound Relationships |
Type |
Active |
Source |
Characteristic |
Refinability |
Group |
Hepatitis B immunoglobulin adverse reaction |
Causative agent (attribute) |
True |
Hepatitis B surface antigen immunoglobulin (substance) |
Inferred relationship |
Some |
1 |
Hepatitis B immunoglobulin allergy |
Causative agent (attribute) |
False |
Hepatitis B surface antigen immunoglobulin (substance) |
Inferred relationship |
Some |
|
poudre de 1000 UI d'immunoglobuline contre l'hépatite B pour solution injectable en flacon |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Hepatitis B surface antigen immunoglobulin (substance) |
Inferred relationship |
Some |
|
poudre de 200 UI d'immunoglobuline contre l'hépatite B pour solution injectable en flacon |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Hepatitis B surface antigen immunoglobulin (substance) |
Inferred relationship |
Some |
|
poudre de 500 UI d'immunoglobuline contre l'hépatite B pour solution injectable en flacon |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Hepatitis B surface antigen immunoglobulin (substance) |
Inferred relationship |
Some |
|
Hepatitis B surface antigen immunoglobulin-containing product |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Hepatitis B surface antigen immunoglobulin (substance) |
Inferred relationship |
Some |
1 |
Anti-hbs immunoglobulin injection |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Hepatitis B surface antigen immunoglobulin (substance) |
Inferred relationship |
Some |
|
flacon de 1 unité d'immunoglobuline contre l'hépatite B |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Hepatitis B surface antigen immunoglobulin (substance) |
Inferred relationship |
Some |
|
flacon d'une solution injectable de 217 U d'immunoglobuline antihépatique B |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Hepatitis B surface antigen immunoglobulin (substance) |
Inferred relationship |
Some |
|
flacon de 1 mL d'une solution injectable de 312 unités/mL d'immunoglobuline contre l'hépatite B |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Hepatitis B surface antigen immunoglobulin (substance) |
Inferred relationship |
Some |
|
flacon de 5 mL d'une solution injectable de 312 unités/mL d'immunoglobuline contre l'hépatite B |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Hepatitis B surface antigen immunoglobulin (substance) |
Inferred relationship |
Some |
|
Hepatitis B immunoglobulin allergy |
Causative agent (attribute) |
False |
Hepatitis B surface antigen immunoglobulin (substance) |
Inferred relationship |
Some |
1 |
Product containing only Hepatitis B surface antigen immunoglobulin (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Hepatitis B surface antigen immunoglobulin (substance) |
Inferred relationship |
Some |
1 |
Allergy to Hepatitis b surface antigen immunoglobulin |
Causative agent (attribute) |
True |
Hepatitis B surface antigen immunoglobulin (substance) |
Inferred relationship |
Some |
1 |
Hepatitis B surface antigen immunoglobulin 312 unit/mL solution for injection |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Hepatitis B surface antigen immunoglobulin (substance) |
Inferred relationship |
Some |
1 |
Hepatitis B surface antigen immunoglobulin 312 unit/mL solution for injection |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Hepatitis B surface antigen immunoglobulin (substance) |
Inferred relationship |
Some |
1 |
Hepatitis B surface antigen immunoglobulin only product in parenteral dose form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Hepatitis B surface antigen immunoglobulin (substance) |
Inferred relationship |
Some |
1 |
Hepatitis B surface antigen immunoglobulin-containing product in parenteral dose form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Hepatitis B surface antigen immunoglobulin (substance) |
Inferred relationship |
Some |
1 |
poudre de 200 UI d'immunoglobuline contre l'hépatite B pour solution injectable en flacon |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Hepatitis B surface antigen immunoglobulin (substance) |
Inferred relationship |
Some |
1 |
poudre de 500 UI d'immunoglobuline contre l'hépatite B pour solution injectable en flacon |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Hepatitis B surface antigen immunoglobulin (substance) |
Inferred relationship |
Some |
1 |
Product containing precisely Hepatitis B surface antigen immunoglobulin 500 unit/1 milliliter conventional release solution for injection (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Hepatitis B surface antigen immunoglobulin (substance) |
Inferred relationship |
Some |
1 |
Product containing precisely Hepatitis B surface antigen immunoglobulin 500 unit/1 milliliter conventional release solution for injection (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Hepatitis B surface antigen immunoglobulin (substance) |
Inferred relationship |
Some |
1 |
Product containing precisely Hepatitis B surface antigen immunoglobulin 50 unit/1 milliliter conventional release solution for injection (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Hepatitis B surface antigen immunoglobulin (substance) |
Inferred relationship |
Some |
1 |
Product containing precisely Hepatitis B surface antigen immunoglobulin 50 unit/1 milliliter conventional release solution for injection (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Hepatitis B surface antigen immunoglobulin (substance) |
Inferred relationship |
Some |
1 |
Product containing precisely Hepatitis B surface antigen immunoglobulin 50 unit/1 milliliter conventional release solution for infusion (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Hepatitis B surface antigen immunoglobulin (substance) |
Inferred relationship |
Some |
1 |
Product containing precisely Hepatitis B surface antigen immunoglobulin 50 unit/1 milliliter conventional release solution for infusion (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Hepatitis B surface antigen immunoglobulin (substance) |
Inferred relationship |
Some |
1 |
Hepatitis B surface antigen immunoglobulin 50 unit/mL solution for infusion and/or injection |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Hepatitis B surface antigen immunoglobulin (substance) |
Inferred relationship |
Some |
1 |
Hepatitis B surface antigen immunoglobulin 50 unit/mL solution for infusion and/or injection |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Hepatitis B surface antigen immunoglobulin (substance) |
Inferred relationship |
Some |
1 |